Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 10;11(3):842.
doi: 10.3390/biomedicines11030842.

Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues

Violetta Rosiek  1 , Ksenia Janas  1 , Beata Kos-Kudła  1
Affiliations

Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues

Violetta Rosiek et al. Biomedicines. .

Abstract

Angiogenic factors (AF) promote vascular formation and may thus support neuroendocrine tumour (NET) development. This study aimed to assess AF serum level changes in NET patients treated with prolonged-acting somatostatin analogues (SSAs). The study enrolled 49 healthy volunteers (Group A) and 56 NET patients: treatment naïve (Group B) and after-SSA treatment in various periods (months): under 12 (Group C), 13-24 (Group D), 25-36 (Group E), 37-60 (Group F), and over 60 months (Group G). The serum vascular endothelial growth factor receptors 2, 3 (VEGF-R2, VEGF-R3), and vascular cell adhesion molecule-1 (VCAM-1) concentrations were tested using the ELISA. We noted significant differences in the concentrations of VEGF-R2, VEGF-R3, and VCAM-1 depending on the SSA treatment duration (p < 0.001). In the studied AFs, the highest decreasing levels of VEGF-R2 were observed after two years of therapy. However, monitoring VEGF-R2, VEGF-R3, and VCAM-1 during SSA treatment did not allow for the identification of good responders for this kind of therapy. Therefore, these biomarker measurements were not helpful in assessing SSA treatment effectiveness in NET patients.

Keywords: VCAM-1; VEGF-R2; VEGF-R3; neuroendocrine tumors; somatostatin analogues.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Changes in vascular endothelial growth factor receptor 2 (VEGF-R2) (a), vascular endothelial growth factor receptor 3 (VEGF-R3) (b), and vascular cell adhesion molecule-1 (VCAM-1) (c) levels during somatostatin analogue (SSAs) treatment in patients with neuroendocrine tumors.
Figure 1
Figure 1
Changes in vascular endothelial growth factor receptor 2 (VEGF-R2) (a), vascular endothelial growth factor receptor 3 (VEGF-R3) (b), and vascular cell adhesion molecule-1 (VCAM-1) (c) levels during somatostatin analogue (SSAs) treatment in patients with neuroendocrine tumors.
Figure 2
Figure 2
Spearman’s Rank Correlations. Spearman’s coefficients of the relationships among analyzed variables in NET patients: VEGF-R2 vs. Treatment duration (the presented correlation is statistically significant, p < 0.05).
See this image and copyright information in PMC

References

    1. Kos-Kudła B., Foltyn W., Malczewska A., Bednarczuk T., Bolanowski M., Borowska M., Chmielik E., Ćwikła J.B., Gisterek I., Handkiewicz-Junak D., et al. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) Endokrynol. Pol. 2022;73:387–454. doi: 10.5603/EP.a2022.0049. - DOI - PubMed
    1. Kos-Kudła B., Blicharz-Dorniak J., Strzelczyk J., Bałdys-Waligórska A., Bednarczuk T., Bolanowski M., Boratyn-Nowicka A., Borowska M., Cichocki A., Ćwikła J.B., et al. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) Endokrynol. Pol. 2017;68:79–110. doi: 10.5603/EP.2017.0015. - DOI - PubMed
    1. Bednarczuk T., Zemczak A., Bolanowski M., Borowska M., Chmielik E., Ćwikła J.B., Foltyn W., Gisterek I., Handkiewicz-Junak D., Hubalewska-Dydejczyk A., et al. Neuroendocrine neoplasms of the small intestine and the appendix–update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) Endokrynol. Pol. 2022;73:549–583. doi: 10.5603/EP.a2022.0052. - DOI - PubMed
    1. Perez K., Chan J. Medical management of gastrointestinal neuroendocrine tumors. Curr. Opin. Endocrinol. Diabetes Obes. 2022;29:219–224. doi: 10.1097/MED.0000000000000711. - DOI - PubMed
    1. Pavel M., Valle J.W., Eriksson B., Rinke A., Caplin M., Chen J., Costa F., Falkerby J., Fazio N., Gorbounova V., et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy–Biotherapy and Novel Targeted Agents. Neuroendocrinology. 2017;105:266–280. doi: 10.1159/000471880. - DOI - PubMed